share_log

中金:维持同仁堂国药(03613)“跑赢大市”评级 目标价降至11.3港元

CICC: Maintains a "outperform" rating on tongrentangcm (03613) with a target price of HKD 11.3.

Zhitong Finance ·  Sep 4 11:26  · Ratings

CICC lowered the profit forecast for Beijing Tongrentang Pharmaceutical by 9.4% and 7.2% for the next two years.

According to the report from CICC, Tongrentangcm's revenue in the first half of the year decreased by 18.2% year-on-year, and net profit decreased by 17.4%, which is in line with CICC's forecast. Due to the increase in expense ratio, the bank lowered the profit forecast for the group by 9.4% and 7.2% for the next two years, respectively, to 0.595 billion and 0.684 billion RMB. The target price was also adjusted downward by 12.1% to 11.3 Hong Kong dollars, maintaining a 'outperform' rating.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment